Medpace (NASDAQ:MEDP) Rating Increased to Hold at Leerink Partnrs

Medpace (NASDAQ:MEDP - Get Free Report) was upgraded by stock analysts at Leerink Partnrs to a "hold" rating in a report released on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Medpace's Q1 2025 earnings at $3.03 EPS, Q2 2025 earnings at $2.96 EPS, Q3 2025 earnings at $2.92 EPS, Q4 2025 earnings at $3.16 EPS, FY2025 earnings at $12.07 EPS, FY2026 earnings at $12.76 EPS, FY2027 earnings at $13.90 EPS and FY2028 earnings at $15.81 EPS.

MEDP has been the topic of several other reports. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Leerink Partners assumed coverage on shares of Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price on the stock. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $376.30.

Medpace Stock Down 1.3 %

Shares of Medpace stock traded down $4.25 during trading on Monday, reaching $312.36. 343,137 shares of the stock were exchanged, compared to its average volume of 298,736. The firm has a market cap of $9.52 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace has a 1 year low of $302.01 and a 1 year high of $459.77. The stock's fifty day moving average is $335.90 and its 200 day moving average is $339.15.

Remove Ads

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts forecast that Medpace will post 12.29 earnings per share for the current year.

Institutional Investors Weigh In On Medpace

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Medpace by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock valued at $854,087,000 after buying an additional 25,704 shares during the period. Invesco Ltd. increased its position in Medpace by 91.8% during the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after acquiring an additional 519,186 shares during the last quarter. Wasatch Advisors LP lifted its holdings in Medpace by 3.1% in the fourth quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock valued at $311,247,000 after acquiring an additional 28,161 shares during the period. State Street Corp lifted its holdings in Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company's stock valued at $251,337,000 after acquiring an additional 50,312 shares during the period. Finally, Geode Capital Management LLC boosted its position in Medpace by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock worth $218,031,000 after purchasing an additional 28,076 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.